466719378_qzw3tnftlbaknqlfyt2s3jen

.
Name : Mr. GH NABILONE BATKOOT

Lab No. : 466719378 Age : 45 Years
Ref By : SELF Gender : Male
Collected : 14/5/2024 7:33:00AM Reported : 15/5/2024 12:17:26PM
A/c Status : P Report Status : Final
Collected at : LPL-ANANTNAG Processed at : Dr Lal Path Labs
SABA COMPLEX,KHAH BAZAR Khah Bazar, Anantnag, J&K - 192101
ANANTNAG-192101
Test Report
Test Name Results Units Bio. Ref. Interval
SWASTHFIT COMPLETE HEALTH CHECK.
LIVER & KIDNEY PANEL, SERUM
Creatinine 1.36 mg/dL 0.67 - 1.17
GFR Estimated 65 mL/min/1.73m2 >59
GFR Category G2
Urea 51.82 mg/dL 13.00 - 43.00
Urea Nitrogen Blood 24.20 mg/dL 6.00 - 20.00
BUN/Creatinine Ratio 18
Uric Acid 5.95 mg/dL 3.50 - 7.20
AST (SGOT) 25.7 U/L <50
ALT (SGPT) 24.3 U/L <50
GGTP 26.8 U/L <55
Alkaline Phosphatase (ALP) 79.10 U/L 30 - 120
Bilirubin Total 0.39 mg/dL 0.30 - 1.20
Bilirubin Direct 0.05 mg/dL <0.20
Bilirubin Indirect 0.34 mg/dL <1.10
Total Protein 6.45 g/dL 6.40 - 8.30
Albumin 4.24 g/dL 3.50 - 5.20
A : G Ratio 1.92 0.90 - 2.00
Globulin(Calculated) 2.21 gm/dL 2.0 - 3.5
Calcium, Total 9.65 mg/dL 8.80 - 10.60
*466719378* Page 1 of 13
.

Lab No. : 466719378 Age : 45 Years
ANANTNAG-192101
Test Report

Phosphorus 3.91 mg/dL 2.40 - 4.40
Sodium 140.00 mEq/L 136.00 - 146.00
Potassium 5.01 mEq/L 3.50 - 5.10
Chloride 104.00 mEq/L 101.00 - 109.00
*466719378* Page 2 of 13
.

Lab No. : 466719378 Age : 45 Years
ANANTNAG-192101
Test Report
LIPID SCREEN, SERUM

(CHO-POD)
Cholesterol, Total 226.00 mg/dL <200.00
Triglycerides 344.89 mg/dL <150.00
HDL Cholesterol 42.75 mg/dL >40.00
LDL Cholesterol, Calculated 114.27 mg/dL <100.00
VLDL Cholesterol,Calculated 68.98 mg/dL <30.00
Non-HDL Cholesterol 183 mg/dL <130
Note
1. Measurements in the same patient can show physiological & analytical variations. Three serial
samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL& LDL Cholesterol.
2. Additional testing for Apolipoprotein B, hsCRP, Lp(a ) & LP-PLA2 should be considered
among patients with moderate risk for ASCVD for risk refinement.
Treatment Goals as per Lipid Association of India 2020

--------------------------------------------------------------------------------------------
| RISK | TREATMENT GOAL | CONSIDER THERAPY |
| CATEGORY |-----------------------------------------|-------------------------------------|
| | LDL CHOLESTEROL | NON HDL CHLOESTEROL| LDL CHOLESTEROL| NON HDL CHLOESTEROL|
| | (LDL-C)(mg/dL) | (NON HDL-C) (mg/dL)| (LDL-C)(mg/dL) | (NON HDL-C) (mg/dL)|
|------------|--------------------|--------------------|----------------|--------------------|
| Extreme | <50 | <80 | | |
| Risk Group |(Optional goal ≤30) |(Optional goal ≤60) | ≥50 | ≥80 |
| Category A | | | | |
|------------|--------------------|--------------------|----------------|--------------------|
| Extreme | | | | |
| Risk Group | ≤30 | ≤60 | >30 | >60 |
| Category B | | | | |
|------------|--------------------|--------------------|----------------|--------------------|
| Very | <50 | <80 | ≥50 | ≥80 |
| High | | | | |
|------------|--------------------|--------------------|----------------|--------------------|
| High | <70 | <100 | ≥70 | ≥100 |
|------------|--------------------|--------------------|----------------|--------------------|
| Moderate | <100 | <130 | ≥100 | ≥130 |
|------------|--------------------|--------------------|----------------|--------------------|
| Low | <100 | <130 | ≥130* | ≥160* |
--------------------------------------------------------------------------------------------
*In low risk patient, consider therapy after an initial non-pharmacological intervention for at least 3 months
*466719378* Page 3 of 13
.

Lab No. : 466719378 Age : 45 Years
ANANTNAG-192101
Test Report
GLUCOSE, FASTING (F)

(Hexokinase)
Glucose Fasting 89.80 mg/dL 70.00 - 100.00
VITAMIN B12; CYANOCOBALAMIN

(ECLIA)
Vitamin B12; Cyanocobalamin 326.90 pg/mL 211.00 - 946.00
Notes
1. Interpretation of the result should be considered in relation to clinical circumstances.
2. It is recommended to consider supplementary testing with plasma Methylmalonic acid (MMA) or
plasma homocysteine levels to determine biochemical cobalamin deficiency in presence of clinical
suspicion of deficiency but indeterminate levels. Homocysteine levels are more sensitive but MMA is
more specific
3. False increase in Vitamin B12 levels may be observed in patients with intrinsic factor blocking
antibodies, MMA measurement should be considered in such patients
4. The concentration of Vitamin B12 obtained with different assay methods cannot be used
interchangeably due to differences in assay methods and reagent specificity
VITAMIN D, 25 - HYDROXY, SERUM

(ECLIA)
Vitamin D, 25 Hydroxy 67.72 nmol/L 75.00 - 250.00
Interpretation
------------------------------------------------------------------------------------------------
| LEVEL | REFERENCE RANGE IN nmol/L| COMMENTS |
|---------------|--------------------------|-----------------------------------------------------|
| Deficient | < 50 | High risk for developing bone disease |
|---------------|--------------------------|-----------------------------------------------------|
| Insufficient | 50-74 | Vitamin D concentration which normalizes |
| | | Parathyroid hormone concentration |
|---------------|--------------------------|-----------------------------------------------------|
| Sufficient | 75-250 | Optimal concentration for maximal health benefit |
|---------------|--------------------------|-----------------------------------------------------|
| Potential | >250 | High risk for toxic effects |
| intoxication | | |
------------------------------------------------------------------------------------------------
*466719378* Page 4 of 13
.

Lab No. : 466719378 Age : 45 Years
ANANTNAG-192101
Test Report

Note
· The assay measures both D2 (Ergocalciferol) and D3 (Cholecalciferol) metabolites of vitamin D.
· 25 (OH)D is influenced by sunlight, latitude, skin pigmentation, sunscreen use and hepatic function.
· Optimal calcium absorption requires vitamin D 25 (OH) levels exceeding 75 nmol/L.
· It shows seasonal variation, with values being 40-50% lower in winter than in summer.
· Levels vary with age and are increased in pregnancy.
· A new test Vitamin D, Ultrasensitive by LC-MS/MS is also available
THYROID PROFILE,TOTAL, SERUM

(Chemiluminescent Immunoassay)
T3, Total 1.01 ng/mL 0.80 - 2.00
T4, Total 8.49 µg/dL 5.10 - 14.10
TSH 2.35 µIU/mL 0.27 - 4.20
Note
1. TSH levels are subject to circadian variation, reaching peak levels between 2 - 4.a.m. and at a
minimum between 6-10 pm . The variation is of the order of 50% . hence time of the day has
influence on the measured serum TSH concentrations.
2. Alteration in concentration of Thyroid hormone binding protein can profoundly affect Total T3 and/or
Total T4 levels especially in pregnancy and in patients on steroid therapy.
3. Unbound fraction ( Free,T4 /Free,T3) of thyroid hormone is biologically active form and correlate
more closely with clinical status of the patient than total T4/T3 concentration
4. Values <0.03 uIU/mL need to be clinically correlated due to presence of a rare TSH variant in
some individuals
*466719378* Page 5 of 13
.

Lab No. : 466719378 Age : 45 Years
ANANTNAG-192101
Test Report

HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD
(HPLC, NGSP certified)
HbA1c 5.9 % 4.00 - 5.60
Estimated average glucose (eAG) 123 mg/dL
Interpretation
HbA1c result is suggestive of at risk for Diabetes (Prediabetes)/ well controlled Diabetes in a known Diabetic
Interpretation as per American Diabetes Association (ADA) Guidelines
------------------------------------------------------------------------------------------
| Reference Group | Non diabetic | At risk | Diagnosing | Therapeutic goals |
| | adults >=18 years | (Prediabetes) | Diabetes | for glycemic control |
| ----------------|-------------------|---------------|-------------|----------------------|
| HbA1c in % | 4.0-5.6 | 5.7-6.4 | >= 6.5 | <7.0 |
------------------------------------------------------------------------------------------
Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered,
particularly when the HbA1C result does not correlate with the patient’s blood glucose levels.
---------------------------------------------------------------------------------
| FACTORS THAT INTERFERE WITH HbA1C | FACTORS THAT AFFECT INTERPRETATION |
| MEASUREMENT | OF HBA1C RESULTS |
|--------------------------------------|------------------------------------------|
| Hemoglobin variants,elevated fetal | Any condition that shortens erythrocyte |
| hemoglobin (HbF) and chemically | survival or decreases mean erythrocyte |
| modified derivatives of hemoglobin | age (e.g.,recovery from acute blood loss,|
| (e.g. carbamylated Hb in patients | hemolytic anemia, HbSS, HbCC, and HbSC) |
| with renal failure) can affect the | will falsely lower HbA1c test results |
| accuracy of HbA1c measurements | regardless of the assay method used.Iron |
| | deficiency anemia is associated with |
| | higher HbA1c |
---------------------------------------------------------------------------------
*466719378* Page 6 of 13
.

Lab No. : 466719378 Age : 45 Years
ANANTNAG-192101
Test Report

URINE EXAMINATION, ROUTINE; URINE, R/E
(Dipstick, Microscopy)
Physical
Colour Pale Yellow Pale yellow
Specific Gravity 1.025 1.001 - 1.030
pH 5.5 5.0 - 8.0
Chemical
Proteins Negative Negative
Glucose Negative Negative
Ketones Negative Negative
Bilirubin Negative Negative
Urobilinogen Negative Negative
Leucocyte Esterase Negative Negative
Nitrite Negative Negative
Microscopy
R.B.C. Negative 0.0 - 2.0 RBC/hpf
Pus Cells 2-3 WBC/HPF 0-5 WBC / hpf
Epithelial Cells 0-1 Epi Cells/hpf 0.0 - 5.0 Epi

cells/hpf
Casts None seen None seen/Lpf
Crystals Negative None seen
Others None seen None seen
*466719378*
Page 7 of 13
.

Lab No. : 466719378 Age : 45 Years
ANANTNAG-192101
Test Report
HEMOGRAM
(VCS Technology)
Hemoglobin 16.40 g/dL 13.00 - 17.00
Packed Cell Volume (PCV) 47.00 % 40.00 - 50.00
RBC Count 5.13 mill/mm3 4.50 - 5.50
MCV 92.00 fL 83.00 - 101.00
MCH 32.00 pg 27.00 - 32.00
MCHC 34.90 g/dL 31.50 - 34.50
Red Cell Distribution Width (RDW) 11.90 % 11.60 - 14.00
Total Leukocyte Count (TLC) 6.50 thou/mm3 4.00 - 10.00
Differential Leucocyte Count (DLC)

Segmented Neutrophils 54.80 % 40.00 - 80.00
Lymphocytes 35.40 % 20.00 - 40.00
Monocytes 4.70 % 2.00 - 10.00
Eosinophils 5.00 % 1.00 - 6.00
Basophils 0.10 % <2.00
Absolute Leucocyte Count
Neutrophils 3.56 thou/mm3 2.00 - 7.00
Lymphocytes 2.30 thou/mm3 1.00 - 3.00
Monocytes 0.31 thou/mm3 0.20 - 1.00
Eosinophils 0.33 thou/mm3 0.02 - 0.50
Basophils 0.01 thou/mm3 0.02 - 0.10
Platelet Count 111 thou/mm3 150.00 - 410.00
Mean Platelet Volume 10.5 fL 6.5 - 12.0
E.S.R. 3 mm/hr 0 - 15
*466719378* Page 8 of 13
.

Lab No. : 466719378 Age : 45 Years
ANANTNAG-192101
Test Report

Note
1. As per the recommendation of International council for Standardization in Hematology, the differential
leucocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of
blood
2. Test conducted on EDTA whole blood
Dr Showkat Ahmad Mir

MD, Pathology
Chief of Laboratory
Dr Lal PathLabs Ltd
*466719378* Page 9 of 13
.

Lab No. : 466719378 Age : 45 Years
SABA COMPLEX,KHAH BAZAR Bemina Degree College Road, Srinagar,
ANANTNAG-192101 J&K - 190018
Test Report
SWASTHFIT COMPLETE HEALTH CHECK.
C-REACTIVE PROTEIN, CARDIO; hsCRP 0.69 mg/L <1.00

(Immunoturbidimetry)
Interpretation
--------------------------------------------------------------
| CARDIO CRP IN mg/L | CARDIOVASCULAR RISK |
|-----------------------|--------------------------------------|
| <1 | Low |
|-----------------------|--------------------------------------|
| 1-3 | Average |
|-----------------------|--------------------------------------|
| 3-10 | High |
|-----------------------|--------------------------------------|
| >10 | Persistent elevation may represent |
| | Non cardiovascular inflammation |
--------------------------------------------------------------
APOLIPOPROTEINS A1 & B, SERUM

(Immunoturbidometry)
Apolipoprotein (Apo A1) 134 mg/dL 105.00 - 175.00
Apolipoprotein (Apo B) 144 mg/dL 60.00 - 140.00
Apo B / Apo A1 Ratio 1.08 0.35 - 0.98
As per recommendations of National Cholesterol Education Program (NCEP) the clinical

significance of results is as follows:
Apolipoprotein B
-----------------------------------------------------------------------------
| RESULT IN mg/dL | REMARKS |
|--------------------------|-------------------------------------------------|
| <23 |Abetalipoproteinemia/Hypobetalipoproteinemia |
|--------------------------|-------------------------------------------------|
| 23-45 |Hypobetalipoproteinemia |
|--------------------------|-------------------------------------------------|
| 46-135 |Normal |
| -------------------------|-------------------------------------------------|
| >135 |Hyperapobetalipoproteinemia/Increased CAD risk |
--------------------------|-------------------------------------------------
Apo B to A1 Ratio
-------------------------------
| RATIO | REMARKS |
|------------|------------------|
| 0.35-0.98 | Desirable |
*466719378* Page 10 of 13
.

Lab No. : 466719378 Age : 45 Years
ANANTNAG-192101 J&K - 190018
Test Report

|------------|------------------|
| >0.98 |Increased CAD risk|
-------------------------------
*466719378* Page 11 of 13
.

Lab No. : 466719378 Age : 45 Years
ANANTNAG-192101 J&K - 190018
Test Report
AMYLASE, SERUM
(IFCC)
Amylase 80.00 U/L 28.00 - 100.00
IRON STUDIES, SERUM

(TPTZ)
Iron 104.80 µg/dL 65.00 - 175.00
Total Iron Binding Capacity (TIBC) 308.80 µg/dL 250.00 - 425.00
Transferrin Saturation 33.94 % 20.00 - 50.00
Dr Adil Sidique Dr.Sameena Bashir Surma Dr.Shazia Bashir Dr.Zoya Karra

MD, Pathology MD,Pathology MD,Pathology MD PATHOLOGY
Chief of Laboratory Consultant Pathologist Chief of Laboratory Consultant Pathologist
Dr Lal PathLabs Ltd Dr Lal PathLabs Ltd Dr Lal PathLabs Ltd Dr Lal PathLabs Ltd
-------------------------------End of report --------------------------------

AHEEEHAPMKHJBNANLCABDJNCBILLJCECCJKCIKPJNKEDFFFAPPAHEEEHA
BNFFFNBPAPBDIDMGFGEKFGAPAOAHFHALAGJOBCJGNLEKMKJGMPBNFFFNB
CIEGCBFPNNPHFBFOPFIAAJHFJAFEHEDDPKPHENFLMLKIOEFLBKHDEHANP
DJDHAAFNBAGIEDIEHLMELFMFAFHKBKBFJIFEPAPAKCLJPDNLILNBKEMEK
IDJNLHFJONFFDIAFLOLCKPJDLENNOJAHKKMHGMMIPLKGKPNGKFFFOJKNC
OOCBBEFNNICGDIGKIPICGIPBADHFOFAINCFCBKDLALIKONNALNEIPOMKD
PDIMIJFFELOJBKAIEKMEIHEHIHAFJBAKPLEPBLMOOJCHKJFCAJNJIDILD
NJJJAMFNAJOPCADJGANHDLPILKBMFMBFOFCCAMNNIIKNOPNGBNFMBHILL
NKLMFBFALPAGFAAIBPOIHIMKHMNFEKFBJFFLALPFOOBIOCNKDJPHNEKLJ
PMDGECFCEPBJJDCDPALFGPNKBDFKPNJHKEPDCDNLNKCKIGEOCJHKHJANP
PPIKOLFLGKCBMNBMPNNFNJEEINMNHNEBJMEEBFOFPNDMKPFKEPCIGCIEO
MGICGJFCPLDCDJBMHHGNMNAEIEOPPFOEAGNPBLNOOLJBIKNJNKONHDICL
MNNNNNEPCFCPBKOJOCFLHNBHJBAHFHALPKPFCMNLMKJCLFNPAHFHAHIKL
APBBBPAPBDPAEJBHNPBKCJOFAHECHHCAONFEOKPGOLMHNLNFEDFCCBKHH
HHHHHHHPHHPPHPPHHHPPPPHPPHPPPPPPPPPHHHPPPHHHPHPHHHHHPHPHP
*466719378* Page 12 of 13
.

Lab No. : 466719378 Age : 45 Years
ANANTNAG-192101 J&K - 190018
Test Report

IMPORTANT INSTRUCTIONS
ŸTest results released pertain to the specimen submitted .ŸAll test results are dependent on the quality of the sample received by the Laboratory .
ŸLaboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .ŸReport
delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted .ŸCertain tests may require further testing at additional cost
for derivation of exact value. Kindly submit request within 72 hours post reporting.ŸTest results may show interlaboratory variations .ŸThe
Courts/Forum at Delhi shall have exclusive jurisdiction in all disputes /claims concerning the test(s) & or results of test(s).ŸTest results are not valid
for medico legal purposes.ŸThis is computer generated medical diagnostic report that has been validated by Authorized Medical
Practitioner/Doctor. ŸThe report does not need physical signature.
(#) Sample drawn from outside source.
If Test results are alarming or unexpected, client is advised to contact the Customer Care immediately for possible remedial action.
Tel: +91-11-49885050,Fax: - +91-11-2788-2134, E-mail: lalpathlabs@lalpathlabs.com
*466719378* Page 13 of 13

466719378_qzw3tnftlbaknqlfyt2s3jen

Uploaded by

Copyright:

Available Formats

466719378_qzw3tnftlbaknqlfyt2s3jen

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

466719378_qzw3tnftlbaknqlfyt2s3jen

Uploaded by

Copyright:

Available Formats

.

Name : Mr. GH NABILONE BATKOOT

Test Name Results Units Bio. Ref. Interval

SWASTHFIT COMPLETE HEALTH CHECK.

LIVER & KIDNEY PANEL, SERUM

Creatinine 1.36 mg/dL 0.67 - 1.17

GFR Estimated 65 mL/min/1.73m2 >59

Urea 51.82 mg/dL 13.00 - 43.00

Urea Nitrogen Blood 24.20 mg/dL 6.00 - 20.00

Uric Acid 5.95 mg/dL 3.50 - 7.20

AST (SGOT) 25.7 U/L <50

ALT (SGPT) 24.3 U/L <50

GGTP 26.8 U/L <55

Alkaline Phosphatase (ALP) 79.10 U/L 30 - 120

Bilirubin Total 0.39 mg/dL 0.30 - 1.20

Bilirubin Direct 0.05 mg/dL <0.20

Bilirubin Indirect 0.34 mg/dL <1.10

Total Protein 6.45 g/dL 6.40 - 8.30

Albumin 4.24 g/dL 3.50 - 5.20

A : G Ratio 1.92 0.90 - 2.00

Globulin(Calculated) 2.21 gm/dL 2.0 - 3.5

Calcium, Total 9.65 mg/dL 8.80 - 10.60

Name : Mr. GH NABILONE BATKOOT

Test Name Results Units Bio. Ref. Interval

Sodium 140.00 mEq/L 136.00 - 146.00

Potassium 5.01 mEq/L 3.50 - 5.10

Chloride 104.00 mEq/L 101.00 - 109.00

Name : Mr. GH NABILONE BATKOOT

Test Name Results Units Bio. Ref. Interval

LIPID SCREEN, SERUM

Cholesterol, Total 226.00 mg/dL <200.00

Triglycerides 344.89 mg/dL <150.00

HDL Cholesterol 42.75 mg/dL >40.00

LDL Cholesterol, Calculated 114.27 mg/dL <100.00

VLDL Cholesterol,Calculated 68.98 mg/dL <30.00

Non-HDL Cholesterol 183 mg/dL <130

Treatment Goals as per Lipid Association of India 2020

Name : Mr. GH NABILONE BATKOOT

Test Name Results Units Bio. Ref. Interval

GLUCOSE, FASTING (F)

Glucose Fasting 89.80 mg/dL 70.00 - 100.00

VITAMIN B12; CYANOCOBALAMIN

Vitamin B12; Cyanocobalamin 326.90 pg/mL 211.00 - 946.00

VITAMIN D, 25 - HYDROXY, SERUM

Vitamin D, 25 Hydroxy 67.72 nmol/L 75.00 - 250.00

Name : Mr. GH NABILONE BATKOOT

Test Name Results Units Bio. Ref. Interval

THYROID PROFILE,TOTAL, SERUM

T3, Total 1.01 ng/mL 0.80 - 2.00

T4, Total 8.49 µg/dL 5.10 - 14.10

TSH 2.35 µIU/mL 0.27 - 4.20

Name : Mr. GH NABILONE BATKOOT

Test Name Results Units Bio. Ref. Interval

HbA1c 5.9 % 4.00 - 5.60

Estimated average glucose (eAG) 123 mg/dL

Name : Mr. GH NABILONE BATKOOT

Test Name Results Units Bio. Ref. Interval

Colour Pale Yellow Pale yellow

Specific Gravity 1.025 1.001 - 1.030

pH 5.5 5.0 - 8.0